Implications of circadian clocks for the rhythmic delivery of cancer therapeutics

Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences

Volumn 366, Issue 1880, 2008, Pages 3575-3598

  Lévi, Francis ^a,b,c   Altinok, Atilla ^d   Clairambault, Jean ^a,e   Goldbeter, Albert ^d  

^a INSERM   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c HÔPITAL PAUL BROUSSE   (France)

^d UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^e INRIA ROCQUENCOURT   (France)

Author keywords

Cancer; Cell cycle; Chemotherapy; Chronotherapeutics; Circadian; Mathematical models

Indexed keywords

BIOCHEMISTRY; CELL PROLIFERATION; CLOCKS; COMPUTER NETWORKS; CYTOLOGY; ENZYME INHIBITION; FLOW INTERACTIONS; IDENTIFICATION (CONTROL SYSTEMS); PHYSIOLOGY; TUMORS;

CANCER; CELL CYCLE; CHEMOTHERAPY; CHRONOTHERAPEUTICS; CIRCADIAN; MATHEMATICAL MODELS;

STOCHASTIC MODELS;

ANTINEOPLASTIC AGENT; FLUOROURACIL; OXALIPLATIN; PLATINUM COMPLEX;

ANIMAL; BIOLOGICAL RHYTHM; CELL CYCLE; CIRCADIAN RHYTHM; COLORECTAL TUMOR; FEMALE; HUMAN; MALE; MOUSE; NEOPLASM; PATHOLOGY; PATHOPHYSIOLOGY; REVIEW; THEORETICAL MODEL; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL CLOCKS; CELL CYCLE; CIRCADIAN RHYTHM; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; MALE; MICE; MODELS, THEORETICAL; NEOPLASMS; ORGANOPLATINUM COMPOUNDS; TREATMENT OUTCOME;

EID: 51049123421     PISSN: 1364503X     EISSN: None     Source Type: Journal    
DOI: 10.1098/rsta.2008.0114     Document Type: Review

References (57)

1. Altinok, A., Lévi, F. & Goldbeter, A. 2007a A cell cycle automaton model for probing circadian patterns of anticancer drug delivery. Adv. Drug Deliv. Rev. 59, 1036-1053. (doi:10.1016/j.addr.2006.09. 022)
2. Altinok, A., Lévi, F. & Goldbeter, A. 20076 Optimizing temporal patterns of anticancer drug delivery by simulations of a cell cycle automaton. In Biosimulation in drug development (eds M. Bertau, E. Mosekilde & H. V. Westerhoff), pp. 275 297. New York, NY: Wiley-VCH.
3. Basdevant, C., Clairambault, J. & Lévi, F. 2005 Optimisation of time-scheduled regimen for anticancer drug infusion. Math. Model. Numer. Anal. 39, 1069-1086. (doi:10.1051/m2an:2005052)
4. Bekkal Brikci, F., Clairambault, J., Ribba, B. & Perthame, B. 2008 An age- and cyclin-structured cell population model for healthy and tumoral tissues. J. Math. Biol. 57, 91-110. (doi:10.1007/s00285-007-0147x)
5. Bjarnason, G. A. & Jordan, R. 2002 Rhythms in human gastrointestinal mucosa and skin. Chronobiol. Int. 19, 129 140. (doi:10.1081/CBI-120002595)
6. Bjarnason, G. A., Jordan, R. C. K., Wood, P. A., Li, Q., Lincoln, D. W., Sothern, R. B., Hrushesky, W. J. M. & Ben-David, Y. 2001 Circadian expression of clock genes in human oral mucosa and skin. Association with specific cell cycle phases. Am. J. Pathol. 158, 1793-1801.
7. Brooks, R. F., Bennett, D. C. & Smith, J. A. 1980 Mammalian cell cycles need two random transitions. Cell 19, 493-504. (doi: 10.1016/0092-8674(80)90524-3)
8. Cain, S. J. & Chau, P. C. 1997 Transition probability cell cycle model. I. Balanced growth. J. Theor. Biol. 185, 55-67. (doi:10.1006/jtbi.1996.0289)
9. Chen-Goodspeed, M. & Lee, C. C. 2007 Tumour suppression and circadian function. J. Biol. Rhythms 22, 291-298. (doi:10.1177/ 0748730407303387)
10. Clairambault, J. 2007 Modeling oxaliplatin drug delivery to circadian rhythm in drug metabolism and host tolerance. Adv. Drug Deliv. Rev. 59, 1054-1068. (doi:10.1016/j.addr.2006.08.004)
11. Clairambault, J. 2008 A step toward optimization of cancer therapeutics. Physiologically based modelling of circadian control on cell proliferation. IEEE-EMB Mag. 27, 20-24.
12. Clairambault, J., Claude, D., Filipski, E., Granda, T. & Lévi, F. 2003 Toxicité et efficacité antitumourale de l'oxaliplatine sur l'ostéosarcome de Glasgow induit chez la souris: un modèle mathématique. Path. Biol. 51, 212-215. (doi:10.1016/S0369- 8114(03)00045-2)
13. Falcone, A. et al. 2007 Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologic Nord Ovest. J. Clin. Oncol. 25, 1670-1676. (doi:10.1200/JCO.2006.09.0928)
14. Filipski, E., Innominato, P., Wu, M., Li, X. M., Iacobelli, S., Xian, L. J. & Lévi, F. 2005 Effects of light and food schedules on liver and tumor molecular clocks in mice. J. Natl Cancer Inst. 97, 507-517.
15. Gachon, F., Olela, F., Schaad, O., Descombes, P. & Schibler, U. 2006 The circadian PAR-domain basic leucine zipper transcription factors DBP, TEF,and HLF modulate basal and inducible xenobiotic detoxification. Cell Metab. 4, 25-36. (doi:10.1016/j.cmet.2006.04.015)
16. Garufi, C., Bria, E., Vanni, B., Zappalà, A. M., Sperduti, I. & Terzoli, E. 2003 A phase II study of irinotecan plus chronomodulated oxaliplatin, 5-fluorouracil and folinic acid in advanced colorectal cancer patients. Br. J. Cancer 89, 1870-1875. (doi:10.1038/sj.bjc. 6601382)
17. Gery, S., Komatsu, N., Baldjyan, L., Yu, A., Koo, D. & Koeffler, H. 2006 The circadian gene perl plays an important role in cell growth and DNA damage control in human cancer cells. Mol. Cell 22, 375-382. (doi:10.1016/j.molcel.2006.03.038)
18. Giacchetti, S. et al 2006 Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group. J. Clin. Oncol. 24, 3562-3569. (doi:10.1200/JCO.2006.06.1440)
19. Goldbeter, A. & Claude, D. 2002 Time-patterned drug administration: insights from a modeling approach. Chronobiol. Int. 19, 157 175. (doi:10.1081/CBI-120002596)
20. Granda, T. & Lévi, F. 2002 Tumour based rhythms of anticancer efficacy in experimental models. Chronobiol. Int. 19, 21-41. (doi:10.1081/CBI-120002589)
21. Granda, T. G., D'Attino, R. M., Filipski, E., Vrignaud, P., Garufi, C., Terzoli, E., Bissery, M. C. & Lévi, F. 2002 Circadian optimization of irinotecan and oxaliplatin efficacy in mice with Glasgow osteosarcoma. Br. J. Cancer 86, 999-1005. (doi:10.1038/sj.bjc.6600168)
22. Granda, T. G., Liu, X. H., Smaaland, R., Cermakian, N., Filipski, E., Sassone-Corsi, P. & Lévi, F. 2005 Circadian regulation of cell cycle and apoptosis proteins in mouse bone marrow and tumour. FASEB J. 19, 304-306.
23. Hanahan, D. & Weinberg, R. A. 2000 The hallmarks of cancer. A review. Cell 100, 57-70. (doi: 10.1016/S0092-8674(00)81683-9)
24. Harris, B. E., Song, R., Soong, S. J. & Diasio, R. B. 1990 Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res. 50, 197-201.
25. Hirayama, J., Cardone, L., Doi, M. & Sassone-Corsi, P. 2005 Common pathways in circadian and cell cycle clocks: light-dependent activation of Fos/AP-1 in zebrafish controls CRY-la and WEE-1. Proc. Natl Acad. Sci. USA 102, 10194-10199. (doi:10.1073/pnas.0502610102)
26. Iacobelli, S., Innominato, P., Piantelli, M., Bjarnason, G., Coudert, B., Focan, C., Giacchetti, S., Poncent, A., Garufi, C., Lévi, F. & ARTBC Chronotherapy Group 2008 Tumor clock protein PER2 as a determinant of survival in patients (pts) receiving oxaliplatin-5-FU-leucovorin as 1st line chemotherapy for metastatic colorectal cancer (MCC). In Proc. American Society of Clinical Oncology, 44th Annual Meeting, Chicago, IL, 30 May-3 June, Abstract 11032.
27. Iurisc, I., Filipski, E., Reinhardt, J., Bach, S., Gianella-Borradori, A., Iacobelli, S., Meijer, L. & Lévi, F. 2006 Improved tumor control through circadian clock induction by seliciclib, a cyclindependent kinase inhibitor. Cancer Res. 66, 10 720-10 728. (doi:10.1158/0008-5472. CAN-06-2086)
28. Koyanagi, S., Kuramoto, Y., Nakagawa, H., Aramaki, H., Ohdo, S., Soeda, S. & Shimeno, H. 2003 A molecular mechanism regulating circadian expression of vascular endothelial growth factor in tumour cells. Cancer Res. 63, 7277-7283.
29. Lemmer, B. 2007 Chronobiology, drug-delivery, and chronotherapeutics. Adv. Drug Deliv. Rev. 59, 825-827. (doi:10.1016/j.addr.2007.08. 001)
30. Lévi, F. 2001 Circadian chronotherapy for human cancers. Lancet Oncol. 2, 307-315. (doi: 10.1016/S1470-2045(00)00326-0)
31. Lévi, F. & Schibler, U. 2007 Circadian rhythms: mechanisms and therapeutic implications. Annu. Rev. Pharmacol. Toxicol. 47, 593-628. (doi:10.1146/annurev.pharmtox.47.120505.105208)
32. Lévi, F. et al. 1992 A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid and oxaliplatin using an ambulatory multichannel programmable pump: high antitumour effectiveness against metastatic colorectal cancer. Cancer 69, 893-900. (doi: 10.1002/1097-0142(19920215)69:4 〈 893:: AID-CNCR2820690410〉3.0.CO;2-X)
33. Lévi, F., Zidani, R. & Misset, J.-L. 1997 Randomized multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet 350, 681-686. (doi:10.1016/s0140-6736(97)03358-8)
34. Lévi, F., Metzger, G., Massari, C. & Milano, G. 2000 Oxaliplatin: pharmacokinetics and chronopharmacological aspects. Clin. Pharmacokinet. 38, 1 21. (doi:10.2165/00003088-200038010-00001)
35. Lévi, F., Filipski, E., Iurisci, I., Li, X. M. & Innominato, P. 2007a Crosstalks between circadian timing system and cell division cycle determine cancer biology and therapeutics. Cold Spring Harb. Symp. Quant. Biol. 72, 465-475. (doi:10.1101/sqb.2007.72.030)
36. Lévi, F., Focan, C., Karaboué, A., de la Valette, V., Focan-Henrard, D., Baron, B., Kreutz, M. & Giacchetti, S. 20076 Implications of circadian clocks for the rhythmic delivery of cancer therapeutics. Adv. Drug Deliv. Rev. 59, 1015-1035. (doi:10.1016/j.addr.2006.11.001)
37. Li, X. M., Metzger, G., Filipski, E., Lemaigre, G. & Lévi, F. 1998 Modulation of nonprotein sulphydryl compounds rhythm with buthionine sulphoximine: relationship with oxaliplatin toxicity in mice. Arch. Toxicol. 72, 574-579. (doi:10.1007/s002040050545)
38. Liu, A. C., Lewis, W. G. & Kay, S. A. 2007 Mammalian circadian signaling networks and therapeutic targets. Nat. Chem. Biol. 3, 630-639. (doi:10.1038/nchembio.2007.37)
39. 6-alkylguanine-DNA alkyltransferase activity in circulating blood mononuclear cells of healthy human subjects. Int. J. Cancer 91, 60-66. (doi:10.1002/1097-0215(20010101)91:1〈60::AID- I.JC1010〉3.0.CO;2-N)
40. Matsuo, T., Yamaguchi, S., Mitsui, S., Emi, A., Shimoda, F. & Okamura, H. 2003 Control mechanism of the circadian clock for timing of cell division in vivo. Science 302, 255-259. (doi:10.1126/science. 1086271)
41. Mormont, M. C. & Lévi, F. 2003 Cancer chronotherapy: principles, applications, and perspectives. Cancer 97, 155-169. (doi: 10.1002/cncr.11040)
42. Mormont, M. C. et al. 2000 Marked 24-h rest/activity rhythms are associated with better quality of life, better response and longer survival in patients with metastatic colorectal cancer and good performance status. Clin. Cancer Res. 6, 3038-3045.
43. Naguib, F. N., Soong, S. J. & el Kouni, M. H. 1993 Circadian rhythm of orotate phosphoribosyltransferase, pyrimidine nucleoside phosphorylases and dihydrouracil dehydrogenase in mouse liver. Possible relevance to chemotherapy with 5-fluoropyrimidines. Biochem. Pharmacol. 45, 667-673. (doi:10.1016/0006-2952(93)90141-I)
44. Nowakowska-Dulawa, E. 1990 Circadian rhythm in 5-fluorouracil (FU) pharmacokinetics and tolerance. Chronobiologia 17, 27-35.
45. Oklejewicz, M., Destici, E., Tamanini, F., Hut, R. A., Janssens, R. & van der Horst, G. T. 2008 Phase resetting of the mammalian circadian clock by DNA damage. Curr. Biol. 18, 286-291. (doi:10.1016/j.cub.2008.01. 047)
46. Okyar, A. & Lévi, F. 2008 Circadian control of cell cycle pathways: relevance for cancer chronotherapeutics. In Trends in cell cycle research (ed. K. Yoshida), Ch. 15, pp. 327-351. Trivandrum, India: Research Signpost.
47. Peters, G. J., Van Dijk, J., Nadal, J. C., Van Groeningen, C. J., Lankelma, J. & Pinedo, H. M. 1987 Diurnal variation in the therapeutic efficacy of 5-fluorouracil against murine colon cancer. In Vivo 1, 113-117.
48. Porsin, B., Formento, J. L., Filipski, E., Etienne, M. C., Francoual, M., Renée, N., Lévi, F. & Milano, G. 2003 Dihydropyrimidine dehydrogenase circadian rhythm in both enzyme activity and gene expression from mouse liver. Eur. J. Cancer 39, 822-828. (doi:10.1016/S0959-8049 (02)00598-1)
49. Reddy, A. B., Wong, G. K. Y., O'Neill, J., Maywood, E. S. & Hastings, M. H. 2005 Circadian clocks: neural and peripheral pacemakers that impact upon the cell division cycle. Mutat. Res. 574, 76-91.
50. Smaaland, R., Sothern, R. B., Laerum, O. D. & Chronobiol, J. F. 2002 Rhythms in human bone marrow and blood cells. Chronobiol Int. 19, 101-127. (doi:10.1081/CBI-120002594)
51. Smith, J. A. & Martin, L. 1973 Do cells cycle? Proc. Natl Acad. Sci. USA 70, 1263-1267. (doi: 10.1073/pnas.70.4.1263)
52. Smolensky, M. & Peppas, N. 2007 Chronobiology, drug delivery, and chronotherapeutics. Adv. Drug Deliv. Rev. 59, 828-851. (doi:10.1016/j.addr.2007.07.001)
53. Voland, C., Bord, A., Péleraux, A., Pénarier, G., Carrière, D., Galiègue, S., Cvitkovic, E., Jbilo, O. &: Casellas, P. 2006 Repression of cell cycle-related proteins by oxaliplatin but not cisplatin in human colon cancer cells. Mol. Cancer Ther. 5, 2149-2157. (doi:10.1158/1535-7163.MCT-05-0212)
54. Weitzman, E. D., Fukushima, D., Nogeire, C., Roffwarg, H., Gallagher, T. F. & Hellman, L. 1971 Twenty-four hour pattern of the episodic secretion of Cortisol in normal subjects. J. Clin. Endocrinol Metab. 33, 14-22.
55. Wood, P. A., Du-Quiton, J., You, S. & Hrushesky, W. J. 2006 Circadian clock coordinates cancer cell cycle progression, thymidylate synthase, and 5-fluorouracil therapeutic index. Mol. Cancer Ther. 8, 2023-2033. (doi':10.1158/1535-7163.MCT-06-0177)
56. You, S., Wood, P. A., Xiong, Y., Kobayashi, M., Du-Quiton, J. & Hrushesky, W. J. 2005 Daily coordination of cancer growth and circadian clock gene expression. Breast Cancer Res. Treat. 91, 47-60. (doi:10.1007/s10549-004-6603-z)
57. Zeng, Z. L., Sun, J., Guo, L., Li, S., Wu, M. W., Qiu, F., Jiang, W. Q., Lévi, F. & Xian, L. J. 2005 Circadian rhythm in dihydropyrimidine dehydrogenase activity and reduced glutathione content in peripheral blood of nasopharyngeal carcinoma patients. Chronobiol. Int. 22, 741-754. (doi:10.108/07420520500179969)